Biologics Contract Development Market Research Report
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Biologics Contract Development Market, By Source
7.1. Biologics Contract Development Market, By Source Type, 2020-2030
7.1.1. Microbial
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Mammalian
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. Others
7.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Biologics Contract Development Market, By Product Service Type
8.1. Biologics Contract Development Market, By Product Service Type, 2020-2030
8.1.1. Cell Line Development
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Process Development
8.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Biologics Contract Development Market, By Disease Indication
9.1. Biologics Contract Development Market, By Disease Indication, 2020-2030
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. Immunological disorders
9.1.2.1. Market Revenue and Forecast (2016-2030)
9.1.3. Cardiovascular disorders
9.1.3.1. Market Revenue and Forecast (2016-2030)
9.1.4. Hematological disorders
9.1.4.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global Biologics Contract Development Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, By Source (2016-2030)
10.1.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.1.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, By Source (2016-2030)
10.1.4.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.1.4.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, By Source (2016-2030)
10.1.5.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.1.5.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, By Source (2016-2030)
10.2.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.2.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, By Source (2016-2030)
10.2.4.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.2.4.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, By Source (2016-2030)
10.2.5.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.2.5.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, By Source (2016-2030)
10.2.6.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.2.6.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, By Source (2016-2030)
10.2.7.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.2.7.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, By Source (2016-2030)
10.3.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.3.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, By Source (2016-2030)
10.3.4.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.3.4.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, By Source (2016-2030)
10.3.5.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.3.5.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, By Source (2016-2030)
10.3.6.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.3.6.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, By Source (2016-2030)
10.3.7.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.3.7.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, By Source (2016-2030)
10.4.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.4.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, By Source (2016-2030)
10.4.4.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.4.4.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, By Source (2016-2030)
10.4.5.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.4.5.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, By Source (2016-2030)
10.4.6.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.4.6.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, By Source (2016-2030)
10.4.7.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.4.7.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, By Source (2016-2030)
10.5.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.5.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, By Source (2016-2030)
10.5.4.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.5.4.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, By Source (2016-2030)
10.5.5.2. Market Revenue and Forecast, By Product Service Type (2016-2030)
10.5.5.3. Market Revenue and Forecast, By Disease Indication (2016-2030)
Chapter 11. Company Profiles
11.1. WuXi Biologics
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Abzena Ltd.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Fujifilm Diosynth Biotechnologies
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. KBI Biopharma
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. AGC Biologics
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. SE Thermo Fisher (Patheon)
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. LakePharma
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Genscript Biotech Corporation
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Bionova Scientific
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Boehringer Ingelheim BioXcellence
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. STC Biologics, Inc.
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers